AI startup Cleerly raises $106M for heart disease detection

Cleerly, an AI-driven cardiovascular imaging startup, has raised $106 million in a Series C extension round led by Insight Partners. The company, founded by cardiologist James Min, uses advanced software to analyze CT scans and detect early-stage coronary artery disease before symptoms appear. This innovative approach aims to improve preventive care for heart conditions, which remain the leading cause of death in the US.

The technology has already received FDA clearance for diagnosing symptomatic patients and recently gained Medicare approval for its plaque analysis test. Cleerly’s software provides a less invasive and more accurate alternative to traditional diagnostics like stress tests or angiograms. With a compounded annual growth rate exceeding 100% over the past four years, the company is poised to expand further as health insurers increasingly cover its tests.

The latest funding will support Cleerly’s ongoing multi-site clinical trials and future growth. Insight Partners’ involvement highlights the growing confidence in AI-driven solutions for healthcare. While facing competition from companies like HeartFlow and Elucid, Cleerly’s goal of screening the global population for heart disease positions it as a potential leader in this emerging market.